Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing
NEW YORK, Aug. 10, 2026, 4:06 p.m. EDT — Silence Therapeutics plc jumped over 25% in late trading on Monday as the company reported its investigational RNA-interference drug divesiran reached all primary and secondary endpoints in a randomized Phase 2 polycythemia vera trial. While overall efficacy was notable, investors appeared to focus on a less obvious outcome: the therapy showed sustained activity with dosing every 12 weeks.
